[1]
|
Callander, N.S., Baljevic, M., Adekola, K., et al. (2022) NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 20, 8-19. https://doi.org/10.6004/jnccn.2022.0002
|
[2]
|
Joshua, D.E., Bryant, C., Dix, C., et al. (2019) Biology and Therapy of Multiple Myeloma. Medical Journal of Australia, 210, 375-380. https://doi.org/10.5694/mja2.50129
|
[3]
|
郝牧, 邱录贵. 多发性骨髓瘤肿瘤生物学研究进展[J]. 中国细胞生物学学报, 2022, 44(1): 111-119.
|
[4]
|
Kumar, S., Rajkumar, S.V., Kyle, R.A., et al. (2005) Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. Journal of Clinical Oncology, 23, 5668-5674. https://doi.org/10.1200/JCO.2005.03.159
|
[5]
|
Bianchi, G., Kyle, R.A., Larson, D.R., et al. (2013) High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma. Leukemia, 27, 680-685. https://doi.org/10.1038/leu.2012.237
|
[6]
|
Gonsalves, W.I., Rajkumar, S.V., Dispenzieri, A., et al. (2017) Quantification of Circulating Clonal Plasma Cells via Multiparametric Flow Cytometry Identifies Patients with Smoldering Multiple Myeloma at High Risk of Progression. Leukemia, 31, 130-135. https://doi.org/10.1038/leu.2016.205
|
[7]
|
Pardanani, A., Witzig, T.E., Schroeder, G., et al. (2003) Circulating Peripheral Blood Plasma Cells as a Prognostic Indicator in Patients with Primary Systemic Amyloidosis. Blood, 101, 827-830. https://doi.org/10.1182/blood-2002-06-1698
|
[8]
|
中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订) [J]. 中华内科杂志, 2022, 61(5): 480-487.
|
[9]
|
An, G., Qin, X., Acharya, C., et al. (2015) Multiple Myeloma Patients with Low Proportion of Circulating Plasma Cells Had Similar Survival with Primary Plasma Cell Leukemia Patients. Annals of Hematology, 94, 257-264. https://doi.org/10.1007/s00277-014-2211-0
|
[10]
|
Kopp, H.G., Yildirim, S., Weisel, K.C., et al. (2009) Contamination of Autologous Peripheral Blood Progenitor Cell Grafts Predicts Overall Survival after High-Dose Chemotherapy in Multiple Myeloma. Journal of Cancer Research and Clinical Oncology, 135, 637-642. https://doi.org/10.1007/s00432-008-0499-7
|
[11]
|
Waszczuk-Gajda, A., Feliksbrot-Bratosiewicz, M., Król, M., et al. (2018) Influence of Clonal Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts on Progression and Survival in Multiple Myeloma Patients after Autologous Peripheral Blood Stem Cell Transplantation in Long-Term Observation. Transplantation Proceedings, 50, 2202-2211. https://doi.org/10.1016/j.transproceed.2018.02.131
|
[12]
|
Chakraborty, R., Muchtar, E., Kumar, S.K., et al. (2016) Risk Stratification in Myeloma by Detection of Circulating Plasma Cells Prior to Autologous Stem Cell Transplantation in the Novel Agent Era. Blood Cancer Journal, 6, e512. https://doi.org/10.1038/bcj.2016.117
|
[13]
|
Bae, M.H., Park, C.J., Kim, B.H., et al. (2018) Increased Circulating Plasma Cells Detected by Flow Cytometry Predicts Poor Prognosis in Patients with Plasma Cell Myeloma. Cytometry Part B: Clinical Cytometry, 94, 493-499. https://doi.org/10.1002/cyto.b.21606
|
[14]
|
Sanoja-Flores, L., Flores-Montero, J., Garcés, J.J., et al. (2018) Next Generation Flow for Minimally-Invasive Blood Characterization of MGUS and Multiple Myeloma at Diagnosis Based on Circulating Tumor Plasma Cells (CTPC). Blood Cancer Journal, 8, Article No. 117. https://doi.org/10.1038/s41408-018-0153-9
|
[15]
|
Yao, W., Yang, H., You, H., et al. (2023) The Prognostic Significance of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients. Frontiers in Oncology, 13, Article 1266868. https://doi.org/10.3389/fonc.2023.1266868
|
[16]
|
Bertamini, L., Oliva, S., Rota-Scalabrini, D., et al. (2022) High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 40, 3120-3131. https://doi.org/10.1200/JCO.21.01393
|
[17]
|
Kostopoulos, I.V., Ntanasis-Stathopoulos, I., Rousakis, P., et al. (2023) Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. Journal of Clinical Oncology, 41, 708-710. https://doi.org/10.1200/JCO.22.01606
|
[18]
|
Chakraborty, R. and Lentzsch, S. (2022) Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? Journal of Clinical Oncology, 40, 3099-3102. https://doi.org/10.1200/JCO.22.01040
|
[19]
|
Li, J., Wang, N., Tesfaluul, N., et al. (2017) Prognostic Value of Circulating Plasma Cells in Patients with Multiple Myeloma: A Meta-Analysis. PLOS ONE, 12, e0181447. https://doi.org/10.1371/journal.pone.0181447
|
[20]
|
Chakraborty, R., Muchtar, E., Kumar, S.K., et al. (2017) Serial Measurements of Circulating Plasma Cells before and after Induction Therapy Have an Independent Prognostic Impact in Patients with Multiple Myeloma Undergoing Upfront Autologous Transplantation. Haematologica, 102, 1439-1445. https://doi.org/10.3324/haematol.2017.166629
|
[21]
|
Han, W., Jin, Y., Xu, M., et al. (2021) Prognostic Value of Circulating Clonal Plasma Cells in Newly Diagnosed Multiple Myeloma. Hematology, 26, 510-517. https://doi.org/10.1080/16078454.2021.1948208
|
[22]
|
Xia, Y., Shen, N., Zhang, R., et al. (2023) High-Risk Multiple Myeloma Predicted by Circulating Plasma Cells and Its Genetic Characteristics. Frontiers in Oncology, 13, Article 1083053. https://doi.org/10.3389/fonc.2023.1083053
|
[23]
|
Tian, M., Liang, X., Xu, W., et al. (2023) More than 2% Circulating Plasma Cells as a Prognostic Biomarker in a Large Cohort of Patients with Newly-Diagnosed Multiple Myeloma. Annals of Hematology, 102, 2943-2945. https://doi.org/10.1007/s00277-023-05362-8
|
[24]
|
Dreyfus, F., Ribrag, V., Leblond, V., et al. (1995) Detection of Malignant B Cells in Peripheral Blood Stem Cell Collections after Chemotherapy in Patients with Multiple Myeloma. Bone Marrow Transplantation, 15, 707-711.
|
[25]
|
Gertz, M., Witzig, T., Pineda, A., et al. (1997) Monoclonal Plasma Cells in the Blood Stem Cell Harvest from Patients with Multiple Myeloma Are Associated with Shortened Relapse-Free Survival after Transplantation. Bone Marrow Transplantation, 19, 337-342. https://doi.org/10.1038/sj.bmt.1700670
|
[26]
|
López-Pérez, R., García-Sanz, R., González, D., et al. (2000) The Detection of Contaminating Clonal Cells in Apheresis Products Is Related to Response and Outcome in Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Leukemia, 14, 1493-1499. https://doi.org/10.1038/sj.leu.2401862
|
[27]
|
Cowan, A.J., Stevenson, P.A., Libby, E.N., et al. (2018) Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients Is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. Biology of Blood and Marrow Transplantation, 24, 1386-1391. https://doi.org/10.1016/j.bbmt.2018.02.017
|
[28]
|
Vogel, W., Kopp, H.G., Kanz, L., et al. (2005) Myeloma Cell Contamination of Peripheral Blood Stem-Cell Grafts Can Predict the Outcome in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Journal of Cancer Research and Clinical Oncology, 131, 214-218. https://doi.org/10.1007/s00432-004-0635-y
|
[29]
|
Ho, J., Yang, L., Banihashemi, B., et al. (2009) Contaminating Tumour Cells in Autologous PBSC Grafts Do Not Influence Survival or Relapse Following Transplant for Multiple Myeloma or B-Cell Non-Hodgkin’s Lymphoma. Bone Marrow Transplantation, 43, 223-228. https://doi.org/10.1038/bmt.2008.318
|
[30]
|
Peceliunas, V., Janiulioniene, A., Matuzeviciene, R., et al. (2012) Circulating Plasma Cells Predict the Outcome of Relapsed or Refractory Multiple Myeloma. Leukemia & Lymphoma, 53, 641-647. https://doi.org/10.3109/10428194.2011.627481
|
[31]
|
Vagnoni, D., Travaglini, F., Pezzoni, V., et al. (2015) Circulating Plasma Cells in Newly Diagnosed Symptomatic Multiple Myeloma as a Possible Prognostic Marker for Patients with Standard-Risk Cytogenetics. British Journal of Haematology, 170, 523-531. https://doi.org/10.1111/bjh.13484
|
[32]
|
Kostopoulos, I.V., Eleutherakis-Papaiakovou, E., Rousakis, P., et al. (2021) Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 13, Article 4047. https://doi.org/10.3390/cancers13164047
|
[33]
|
Pasvolsky, O., Milton, D.R., Rauf, M., et al. (2023) Impact of Clonal Plasma Cells in Autografts on Outcomes in High-Risk Multiple Myeloma Patients. Blood Cancer Journal, 13, Article No. 68. https://doi.org/10.1038/s41408-023-00842-6
|
[34]
|
Gonsalves, W.I., Morice, W.G., Rajkumar, V., et al. (2014) Quantification of Clonal Circulating Plasma Cells in Relapsed Multiple Myeloma. British Journal of Haematology, 167, 500-505. https://doi.org/10.1111/bjh.13067
|
[35]
|
Paiva, B., Paino, T., Sayagues, J.M., et al. (2013) Detailed Characterization of Multiple Myeloma Circulating Tumor Cells Shows Unique Phenotypic, Cytogenetic, Functional, and Circadian Distribution Profile. Blood, 122, 3591-3598. https://doi.org/10.1182/blood-2013-06-510453
|
[36]
|
Bal, S., Landau, H.J., Shah, G.L., et al. (2020) Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 26, 1394-1401. https://doi.org/10.1016/j.bbmt.2020.04.011
|